{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:39Z","timestamp":1786119159859,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Cholestatic diseases are characterized by toxic bile acid (BA) accumulation, and abnormal BA composition, which subsequently lead to liver injury. Biochemical synthetic\n                    <jats:italic>Calculus Bovis Sativus<\/jats:italic>\n                    (CBS) is derived from natural\n                    <jats:italic>Calculus Bovis<\/jats:italic>\n                    , a traditional Chinese medicine, which has been used to treat hepatic diseases for thousands of years. Although it has been shown that CBS administration to 17\u03b1-ethinylestradiol (EE)-induced cholestatic rats improves bile flow and liver injury, the involved underlying mechanism is largely unknown. In this study, we showed that CBS administration to EE-induced cholestatic rats significantly decreased serum and hepatic BA levels and reversed hepatic BA composition. DNA microarray analysis suggested that the critical pathways enriched by CBS treatment were bile secretion and primary BA synthesis. These findings led us to focus on the effects of CBS on regulating BA homeostasis, including BA transport, synthesis and metabolism. CBS enhanced hepatic BA secretion by inducing efflux transporter expression and inhibiting uptake transporter expression. Moreover, CBS reduced BA synthesis by repressing the expression of BA synthetic enzymes, CYP7A1 and CYP8B1, and increased BA metabolism by inducing the expression of metabolic enzymes, CYP3A2, CYP2B10, and SULT2A1. Mechanistic studies indicated that CBS increased protein expression and nuclear translocation of hepatic and intestinal farnesoid X receptor (FXR) to regulate the expression of these transporters and enzymes. We further demonstrated that beneficial effects of CBS administration on EE-induced cholestatic rats were significantly blocked by guggulsterone, a FXR antagonist. Therefore, CBS improved BA homeostasis through FXR-mediated signaling in estrogen-induced cholestatic rats. Together, these findings suggested that CBS might be a novel and potentially effective drug for the treatment of cholestasis.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2019.00048","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:24:54Z","timestamp":1549002294000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Calculus Bovis Sativus Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats With Estrogen-Induced Cholestasis"],"prefix":"10.3389","volume":"10","author":[{"given":"Dong","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"B1","first-page":"65","article-title":"Progress research on pharmacology of Calculus bovis and its role on anti-hepatic injury.","volume":"33","author":"Bai","year":"2011","journal-title":"Hubei J. Tradit. Chin. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"key":"B3","article-title":"Research on Calculus bovis.","volume":"12","author":"Chen","year":"1987","journal-title":"Zhong Yao Tong Bao"},{"key":"B4","first-page":"273","article-title":"Clinical observation of bezoar cultivated in vitro for treating chronic hepatitis B with syndrome of damp and heat retention.","volume":"24","author":"Cheng","year":"2014","journal-title":"Chin. J. Integr. Tradit. West. Med. Liver Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","article-title":"Bile acid metabolism and signaling.","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","article-title":"Bile acid nuclear receptor FXR and digestive system diseases.","volume":"5","author":"Ding","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25125","DOI":"10.1074\/jbc.M201323200","article-title":"Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes.","volume":"277","author":"Drocourt","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.1039\/c5ay01288k","article-title":"Development of a rapid and simple LC-MS\/MS method for identification and quality control of natural Calculus bovis and Calculus bovis sativus.","volume":"7","author":"Feng","year":"2015","journal-title":"Anal. Methods"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1517\/14728222.2014.956087","article-title":"Targeting FXR in cholestasis: hype or hope.","volume":"18","author":"Fiorucci","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"B10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4155\/FMC.12.41","article-title":"Farnesoid X receptor: from medicinal chemistry to clinical applications.","volume":"4","author":"Fiorucci","year":"2012","journal-title":"Future Med. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0009-8981(96)06305-X","article-title":"Hepatic levels of bile acids in end-stage chronic cholestatic liver disease.","volume":"251","author":"Fischer","year":"1996","journal-title":"Clin. Chim. Acta"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/hep.26894","article-title":"Peroxisome proliferator-activated receptor alpha activates human multidrug resistance transporter 3\/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.","volume":"59","author":"Ghonem","year":"2014","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis.","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond.","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1021\/ac503816u","article-title":"Metabolic profiling of bile acids in human and mouse blood by LC-MS\/MS in combination with phospholipid-depletion solid-phase extraction.","volume":"87","author":"Han","year":"2015","journal-title":"Anal. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/dmd.108.025155","article-title":"Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes.","volume":"37","author":"Han","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.2147\/DDDT.S150187","article-title":"Hepatoprotective effect of Calculus bovis sativus on nonalcoholic fatty liver disease in mice by inhibiting oxidative stress and apoptosis of hepatocytes.","volume":"11","author":"He","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease.","volume":"65","author":"Jansen","year":"2017","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.7501\/j.issn.0253-2670.2018.10.029","article-title":"Simultaneous quantification of 26 bile acids in Calculus bovis sativus and Calculus bovis by HPLC-MS\/MS.","volume":"49","author":"Kai","year":"2018","journal-title":"Chin. Trad. Herbal Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1074\/jbc.M109326200","article-title":"Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.","volume":"277","author":"Kast","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice.","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/03602532.2012.740048","article-title":"Nuclear receptors in bile acid metabolism.","volume":"45","author":"Li","year":"2013","journal-title":"Drug Metab. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy.","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00204-016-1697-8","article-title":"Role of AMP-activated protein kinase \u03b11 in 17\u03b1-ethinylestradiol-induced cholestasis in rats.","volume":"91","author":"Li","year":"2017","journal-title":"Arch. Toxicol."},{"key":"B26","first-page":"947","article-title":"Analysis of therapeutical effects of Xihuang Pills with intraarterial intervention chemotherapy on 80 cases of advanced primary hepatic carcinoma.","volume":"25","author":"Liu","year":"2010","journal-title":"Chin. J. Tradit. Chin. Med. Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lfs.2014.07.024","article-title":"Beneficial effect of Calculus bovis Sativus on 17\u03b1-ethynylestradiol-induced cholestasis in the rat.","volume":"113","author":"Liu","year":"2014","journal-title":"Life Sci."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-018-0774-9","article-title":"Detection technologies and metabolic profiling of bile acids: a comprehensive review.","volume":"17","author":"Liu","year":"2018","journal-title":"Lipids Health Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/hep.28564","article-title":"Hepatic gene transfer of human aquaporin-1 improves bile salt secretory failure in rats with estrogen-induced cholestasis.","volume":"64","author":"Marrone","year":"2016","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective farnesoid x receptor modulation.","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1007\/s11095-015-1727-x","article-title":"Protective effects of Alisol B 23-Acetate via farnesoid X receptor-mediated regulation of transporters and enzymes in estrogen-induced cholestatic liver injury in mice.","volume":"32","author":"Meng","year":"2015","journal-title":"Pharm. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/jcmm.12401","article-title":"Protective effect of heme oxygenase induction in ethinylestradiol-induced cholestasis.","volume":"19","author":"Muchova","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.10100652","article-title":"Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice.","volume":"258","author":"Muhler","year":"2011","journal-title":"Radiology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5114\/ceji.2014.43723","article-title":"Clinical immunology Immune mechanisms and the role of oxidative stress in intrahepatic cholestasis of pregnancy.","volume":"2","author":"Ozler","year":"2014","journal-title":"Cent. Eur. J. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/jhep.2002.31724","article-title":"Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump.","volume":"35","author":"Plass","year":"2002","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/13543776.2015.1045413","article-title":"Farnesoid X receptor modulators (2011 \u2013 2014): a patent review.","volume":"25","author":"Sepe","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29888","article-title":"Na(+) -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice.","author":"Slijepcevic","year":"2018","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000450983","article-title":"Bile acid uptake transporters as targets for therapy.","volume":"35","author":"Slijepcevic","year":"2017","journal-title":"Dig. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3109\/03602532.2012.748793","article-title":"Nuclear-receptor\u2013mediated regulation of drug\u2013and bile-acid\u2013transporter proteins in gut and liver.","volume":"45","author":"Staudinger","year":"2013","journal-title":"Drug Metab. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis.","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.21494","article-title":"Activation of LXRs prevents bile acid toxicity and cholestasis in female mice.","volume":"45","author":"Uppal","year":"2007","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.29076","article-title":"The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018278","article-title":"Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map.","volume":"6","author":"Wen","year":"2011","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.taap.2015.01.015","article-title":"Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.","volume":"283","author":"Woolbright","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/srep33052","article-title":"Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation.","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2016.10.016","article-title":"Protective effects of SRT1720 via the HNF1\u03b1\/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury.","volume":"264","author":"Yu","year":"2016","journal-title":"Toxicol. Lett."},{"key":"B47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11596-018-1861-x","article-title":"Pharmacokinetic characteristics of baicalin in rats with 17alpha-ethynyl-estradiol-induced intrahepatic cholestasis.","volume":"38","author":"Zhang","year":"2018","journal-title":"Curr. Med. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1476-5381.2008.00030.x","article-title":"Nuclear receptors as therapeutic targets in cholestatic liver diseases.","volume":"156","author":"Zollner","year":"2009","journal-title":"Br. J. Pharmacol."}],"updated-by":[{"DOI":"10.3389\/fphar.2026.1918301","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2019.00048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:53:21Z","timestamp":1786038801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2019.00048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":49,"alternative-id":["10.3389\/fphar.2019.00048"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00048","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]},"article-number":"48"}}